CMP: 410

Glenmark Pharmaceuticals Ltd., is a pharmaceutical company. The Company develops generic drugs for inflammation, metabolic disorders, and pain.

Glenmark is a decent bet in mid-cap pharma space trading at a P/E of nearly 45. It runs at a debt of 476 Crores with 45 Crores cash in hand. Debt levels are safe with Debt to Profits ratio at less than 2 years. Revenues have risen from 802 Crores to 1,564 Crores in the last 5 years. Profits have risen from 135 Crores to 265 Crores in the last 5 years. NPM has stayed around 17% over the last 5 years. Its a decent buy for long term.